CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) will collaborate with Columbia University of New York City to develop drugs that inhibit aldose reductase, an enzyme that causes eye and nerve damage. Aldose reductase inhibitor drugs may treat a number of serious conditions. CSPC will underwrite research carried out by the Organic Chemistry Collaborative Center at Columbia’s Department of Medicine. CSPC will have the right to develop and commercialize OCCC-discovered molecules, which are initially intended for the China market.
Help employers find you! Check out all the jobs and post your resume.